Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) and Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Institutional & Insider Ownership
86.3% of Cullinan Therapeutics shares are owned by institutional investors. 81.0% of Mosaic ImmunoEngineering shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Mosaic ImmunoEngineering and Cullinan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mosaic ImmunoEngineering | N/A | N/A | -1,908.81% |
| Cullinan Therapeutics | N/A | -51.45% | -47.64% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mosaic ImmunoEngineering | N/A | N/A | -$690,000.00 | ($0.09) | -7.49 |
| Cullinan Therapeutics | N/A | N/A | -$219.88 million | ($3.36) | -5.45 |
Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for Mosaic ImmunoEngineering and Cullinan Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mosaic ImmunoEngineering | 0 | 0 | 0 | 0 | 0.00 |
| Cullinan Therapeutics | 1 | 1 | 6 | 0 | 2.63 |
Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 74.88%. Given Cullinan Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Mosaic ImmunoEngineering.
Volatility and Risk
Mosaic ImmunoEngineering has a beta of -0.84, indicating that its stock price is 184% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500.
Summary
Cullinan Therapeutics beats Mosaic ImmunoEngineering on 7 of the 11 factors compared between the two stocks.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
